ClinicalTrials.gg
RecruitingNCT07379333Updated May 13, 2026

A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

A Phase 3 interventional study of HM11260C and Placebo in Type 2 Diabetes, sponsored by Hanmi Pharmaceutical Company Limited. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited — 2 open to participants now, 2 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Hanmi Pharmaceutical Company Limited.

Planned enrollment
5th of 10
118 · median 102
Started
2026
with 1 other
Phase 3
2 of 10
1 open now
Registered
9th of 10
by date

Among the 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited, this one is the 5th largest by planned enrollment, is one of 2 that started in 2026, is one of 2 in phase 3, and was the 9th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Diabetes Mellitus, Type 2 by Hanmi Pharmaceutical Company Limited, or all of them as a file.
02

Study summary

A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Adults aged 19 years or older
  • 2. Diagnosed with type 2 diabetes
  • 3. level 7.0% ≤ HbA1c ≤ 10.0%
  • 4. Stable administration of metformin (≥1,000 mg/day) and dapagliflozin (10 mg/day) without any change in dosage or formulation for at least 8 weeks prior to Visit 1
  • 5. 20 kg/m2 ≤ ≤ 45 kg/m2
  • 6. Agree to the recommended exercise and diet regimen during this clinical trial

Exclusion criteria

Exclusion Criteria:

  • 1. Patients with a history of allergy or resistance to the drug or background therapy
  • 2. Patients diagnosed with a type of diabetes other than type 2 diabetes
  • 3. Patients with uncontrolled severe diabetic complications
  • 4. Patients with a history of acute or chronic metabolic acidosis, including lactic acidosis or diabetic ketoacidosis.
  • 5. Patients with a history of diabetic coma or precoma
  • 6. Those with a history of severe hypoglycemia
  • 7. Those whose weight change > 5 kg
  • 8. History of gastrointestinal disease or surgery
  • 9. History of bariatric surgery
  • 10. History of gallbladder disease
  • 11. History of a disease that could affect the interpretation of
  • 12. History of acute or chronic pancreatitis or pancreatectomy
  • 13. History (including family history) of medullary thyroid cancer (MTC) or multiple endocrine neoplasia (MEN2).
  • 14. Uncontrolled hypertension
  • 15. Severe infections or severe trauma
  • 16. Malnutrition, starvation, or debility, as determined by the investigator.
  • 17. Pituitary or adrenal insufficiency.
  • 18. Tissue hypoxia, such as respiratory failure or shock.
  • 19. History of alcoholism or drug abuse
  • 20. History of malignant tumors
  • 21. Heart failure, Ischemic heart disease, Severe cerebrovascular disease,
  • 22. Patients with one of the following clinical laboratory test results : Amylase or Lipase > 3 X / FPG > 270 mg/dL
  • 23. Patients with severe hepatic impairment or one of the following laboratory test results : or ALT > 3 X ULN / Total > 1.5 X ULN
  • 24. Patients with moderate or severe renal impairment
  • 25. History of Diabetic medications or weight-loss medications
  • 26. Those who have participated in another clinical trial and received investigational drugs within 30 days
  • 27. Pregnant or lactating women, or women of
  • 28. Women of childbearing potential and men who do not consent to the use of the following methods
  • 29. Considered by investigator as not appropriate to participate in the clinical study with other reason.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
118 participants (estimated)

Study arms

  • Experimental
    HM11260C

    Weekly administration by subcutaneous injection

    Drug: HM11260C

  • Placebo comparator
    Placebo

    Weekly administration by subcutaneous injection

    Drug: Placebo

Interventions

  • Test drug

  • DrugPlacebo

    Placebo drug

06

What researchers measure

Primary outcomes

  1. Change in HbA1c at 36 weeks compared to baseline

    Time frame: baseline, 36 weeks

Secondary outcomes

  1. Change from baseline in HbA1c at Week 24

    Time frame: baseline, 24 weeks

  2. Proportion of subjects achieving HbA1c <7.0% at Weeks 24 and 36

    Time frame: 24, 36 weeks

  3. Proportion of subjects achieving HbA1c <6.5% at Weeks 24 and 36

    Time frame: 24, 36 weeks

  4. Change from baseline in FPG at Weeks 24 and 36

    Time frame: baseline, 24, 36 weeks

  5. Proportion of subjects receiving rescue medication at Weeks 24 and 36

    Time frame: 24, 36 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2027, 19 months after the start.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 19 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Jan 30, 2026
StartActual
Apr 13, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Jan 2028
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07379333
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Apr 13, 2026
Primary completion
Nov 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
May 13, 2026

Study contacts

Jee Won Shon
Contact
jeewon.shon@hanmi.co.kr
82-2-410-9037

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efpeglenatide

Start the discussion